RayKnowChina Research Map
Shortlist

RecruitingLymphomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL

An open trial on lymphoma, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of Soochow University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorFirst Affiliated Hospital of Soochow University苏州大学附属第一医院SuzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07255963, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed DLBCL.

    Inclusion criterion 5

  3. Resolution of any prior treatment-related non-hematologic toxicities to Grade ≤1 or baseline.

    Inclusion criterion 8

    Prior treatment failure or resistance to pirtobrutinib or BCL2 inhibitors.

    Exclusion criterion 1

    Prior Anticancer Therapy:Chemotherapy, radiotherapy, immunotherapy, or antibody-based anticancer therapy within the specified washout period.Traditional Chinese herbal medicine with antitumor indications.Small-molecule targeted therapy within 2 weeks before study treatment initiation. ADCs or cytotoxic therapy within 10 weeks before study treatment initiation.

    Exclusion criterion 2

    Participation in another investigational drug study within 4 weeks prior to the first dose of study treatment.

    Exclusion criterion 3

    Systemic corticosteroid therapy (>5 days within 14 days prior to treatment) at doses exceeding >10 mg/day dexamethasone (or equivalent) for CNS disease control.

    Exclusion criterion 4

  4. ECOG performance 0 \~ 3.

    Inclusion criterion 3

  5. PET-CT-defined measurable disease with a short axis diameter of ≥1.5 cm.

    Inclusion criterion 6

  6. Active HBV/HCV:Exceptions. Inactive HBsAg carriers, HBV patients with sustained viral suppression (HBV-DNA < LLOD),HCV-cured patients are allowed.

    Exclusion criterion 8

  7. Women who are pregnant or breastfeeding.

    Exclusion criterion 12

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07255963, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • ≥18 years old.
  • Capable of understanding and voluntarily signing written informed consent.
  • ECOG performance 0 \~ 3.
  • Anticipated survival ≥3 months
  • Histologically or cytologically confirmed DLBCL.
  • PET-CT-defined measurable disease with a short axis diameter of ≥1.5 cm.
  • Have received at least one prior line of systemic therapy for DLBCL.
  • Resolution of any prior treatment-related non-hematologic toxicities to Grade ≤1 or baseline.
  • Adequate Bone Marrow and Organ Function, defined as:

Bone Marrow Function: ANC≥1.5 × 10⁹/L, Platelets ≥80 × 10⁹/L, Hemoglobin ≥80 g/L Hepatic Function: Total bilirubin ≤1.5 × ULN (≤3.0 × ULN if liver metastases present); AST/SGOT and ALT/SGPT ≤2.5 × ULN (≤5.0 × ULN if liver metastases present) Coagulation: INR and aPTT≤1.5 × ULN Renal Function: Serum creatinine ≤1.5 × ULN or estimated creatinine clearance (CrCl) ≥60 mL/min;

  • Subjects with childbearing or childbearing potential must be willing to practice birth control from the date of registration in this study to the follow-up period of the study.
  • Able to swallow tablets/capsules without difficulty.
  • Adhere to scheduled visits, treatment plans, laboratory tests, and other study procedures.

Exclusion Criteria:

  • Prior treatment failure or resistance to pirtobrutinib or BCL2 inhibitors.
  • Prior Anticancer Therapy:Chemotherapy, radiotherapy, immunotherapy, or antibody-based anticancer therapy within the specified washout period.Traditional Chinese herbal medicine with antitumor indications.Small-molecule targeted therapy within 2 weeks before study treatment initiation. ADCs or cytotoxic therapy within 10 weeks before study treatment initiation.
  • Participation in another investigational drug study within 4 weeks prior to the first dose of study treatment.
  • Systemic corticosteroid therapy (>5 days within 14 days prior to treatment) at doses exceeding >10 mg/day dexamethasone (or equivalent) for CNS disease control.
  • Requiring ongoing anticancer therapy.
  • Uncontrolled or Severe Cardiovascular Disease,
  • Active infection requiring IV antibiotics or systemic antimicrobial therapy.
  • Active HBV/HCV:Exceptions. Inactive HBsAg carriers, HBV patients with sustained viral suppression (HBV-DNA < LLOD),HCV-cured patients are allowed.
  • Clinically significant abnormalities affecting drug absorption or prior total gastrectomy/gastric banding.
  • History of hemorrhagic diathesis or requirement for long-term oral anticoagulation.
  • Prior allogeneic hematopoietic stem cell transplantation (HSCT) or planned allogeneic HSCT.
  • Women who are pregnant or breastfeeding.
  • Known allergy to the study drug or its excipients.
  • Active psychiatric illness or history of alcohol/drug abuse .
  • Any uncontrolled illness, organ dysfunction, or medical condition that, in the investigator's judgment, jeopardizes patient safety or adherence to study procedures.
  • Other conditions deemed inappropriate for study participation by the investigator.

Quoted from ClinicalTrials.gov, NCT07255963, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07255963, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07255963